CCO Neuroscience Podcast

In this episode, Dr Robert Cotes and Dr David Goldsmith discuss their clinical experience with long-acting injectable antipsychotic treatments in the Grady Health System, with a focus on communication strategies to educate patients on their treatment options and engage them in shared decision-making. Presenters:  Robert O. Cotes, MD, DFAPA Associate Professor and Distinguished Physician Director, Clinical & Research Program for Psychosis at Grady Health System Director, Project ARROW at Grady Health System Department of Psychiatry and Behavioral Sciences Emory University School of Medicine Atlanta, Georgia David R. Goldsmith, MD, MSc Associate Professor Director, Inflammation, Motivation, and Negative Symptoms of Schizophrenia (InMotioNSS) Lab Co-Director, Clinical & Research Program for Psychosis at Grady Health System Director, PSTAR Clinic at Grady Memorial Hospital Faculty, Emory Behavioral Immunology Program Co-Director, Psychiatry Residency Research Track Department of Psychiatry and Behavioral Sciences Emory University School of Medicine Atlanta, Georgia This content is part of an online CME program supported by educational grants from Indivior Inc.; Otsuka America Pharmaceutical, Inc. and Lundbeck; and Teva Pharmaceuticals.  Link to full program: https://bit.ly/414XkY4 [https://bit.ly/414XkY4]

In this episode, David N. Lieberman, MD, PhD, and Eric Marsh, MD, PhD, discuss recent updates relevant to the treatment of Rett syndrome, including: * The recently updated Comprehensive Care Guidelines from the International Rett Syndrome Foundation, available at rettsyndrome.org * Ongoing collection and analysis of longitudinal data within the Rett Syndrome Natural History Study * Efficacy and safety data from the double-blind, placebo-controlled phase III registrational LAVENDER trial evaluating oral trofinetide, a small molecule analogue of insulin-like growth factor 1 * Topline results from phase III AVATAR and EXCELLENCE trials of the sigma-1 receptor agonist blarcamesine * Several early ongoing gene therapy trials Dr Lieberman and Dr Marsh complement this informative update with wisdom from their own clinical experience to provide a full picture of current treatment and management options available to patients with Rett syndrome. Presenters:  David N. Lieberman, MD, PhD Director, Comprehensive Rett Syndrome Clinic Department of Neurology Boston Children's Hospital Boston, Massachusetts Eric Marsh, MD PhD Clinical Director, Orphan Disease Center Director (MPI), CHOP/Penn IDDRC Professor, Departments of Neurology and Pediatrics Division of Neurology Children’s Hospital of Philadelphia Perelman School of Medicine University of Pennsylvania Philadelphia, Pennsylvania This content is part of an online CME program in partnership with the International Rett Syndrome Foundation and supported by an educational grant from Acadia Pharmaceuticals. Link to full program: https://bit.ly/4fJRRL0 [https://bit.ly/4fJRRL0]

Link to CME: Claim Credit - https://bit.ly/3OByCaE [https://bit.ly/3OByCaE] In this episode, Drs. Halford and Hahn discuss the current treatment landscape of developmental and epileptic encephalopathies (DEEs), such as Lennox-Gastaut syndrome and Dravet syndrome, and the emerging role of brain cholesterol in addressing seizure frequency. The full episode covers: * How to diagnose these epilepsies and the FDA-approved treatment options in the first-line and second-line settings * The role of antiseizure medications in DEE treatment management * The nonpharmacological treatment options available to patients with DEEs * The emerging role of brain cholesterol in neurologic diseases like DEEs and Alzheimer’s disease * Results from the ELEKTRA clinical trial, including cholesterol synthase inhibitors’ impact on seizure frequency * The future of soticlestat as a treatment option for pediatric patients with DEEs Presenters: Jonathan J. Halford, MD Professor Director, Translational Research Unit Department of Neurology Medical University of South Carolina Charleston, SC Cecil Hahn, MD, MPH, FRCPC Professor Pediatric Epileptologist University of Toronto Toronto, Ontario, Canada Content based on an online CME program supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc. Link to full program:  https://bit.ly/45UUpQy [https://bit.ly/45UUpQy]

Link to CME: Claim Credit - https://bit.ly/3wbVkA1 [https://bit.ly/3wbVkA1] In this episode, Drs. Halford and White discuss the emerging role of brain cholesterol in the development and potential treatment of neurological diseases like epilepsy or Alzheimer and Huntington diseases. The full episode covers: * Overview of brain cholesterol and its function in the body * Pathogenesis potential for certain diseases via brain cholesterol * Emerging research on a cholesterol synthase inhibitor as a novel therapy * The future of soticlestat as a potential treatment option for pediatric epilepsies—Lennox-Gastaut syndrome and Dravet syndrome—and other neurological diseases Presenters: Jonathan J. Halford, MD Professor Director, Translational Research Unit Department of Neurology Medical University of South Carolina Charleston, SC H. Steve White, PhD Professor, Department of Pharmacy Co-Director, Center for Epilepsy Drug Discovery School of Pharmacy University of Washington Seattle, Washington

In this episode, Drs. Sabbagh and Isaacson discuss how to best approach Alzheimer’s disease (AD) and mild cognitive impairment (MCI) in clinical practice, including accurately diagnosing patients and optimizing treatment in terms of patient preferences and reimbursement options. The full episode covers: * Defining AD and MCI and their clinical presentation * How to diagnose AD vs MCI * Reimbursement landscape for current diagnosing and monitoring tools * Precision medicine’s evolving role in diagnosing and treating patients with AD and/or MCI   Presenters: Marwan Sabbagh, MD Professor of Neurology Alzheimer’s and Memory Disorders Division Department of Neurology Barrow Neurological Institute Phoenix, Arizona Richard Isaacson MD Director of the Institute for Neurodegenerative Diseases Florida